Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease

To see complete record on, please visit this link

Id: NCT04123314

Organisation Name: Johns Hopkins University

Overal Status: Recruiting

Start Date: March 24, 2021

Last Update: March 24, 2022

Lead Sponsor: Johns Hopkins University

Brief Summary: This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.

  • Depressive Symptoms
  • Depression
  • Alzheimer Disease
  • Mild Cognitive Impairment

Total execution time in seconds: 0.28532695770264